Moderated by:
Barry Jones, Ph.D. – Chief Scientist, Global DMPK at Pharmaron
Dr. Barry Jones is the chief scientist for Pharmaron global DMPK based at Hoddesdon and Rushden in the UK. Prior to this, Barry worked in the pharmaceutical industry firstly at Pfizer Global Research & Development in Sandwich from 1990 to 2011 before joining Astrazeneca in 2011 until 2019.
Throughout his industrial career he has focused on setting strategic direction, identifying new opportunities for research/development programs and adding significant insight/expertise and value to drug discovery and development projects with a focus in the area of in vitro DMPK science and drug-drug interactions. Barry gained his Ph. D. from the University of Surrey following research into cytochrome P450-mediated N-dealkylation 1990. He is a long-standing member of the Xenobiotica editorial board and has authored or co-authored more than 80 publications.
Speakers:
Allan E. Rettie – Professor Medicinal Chemistry at the University of Washington
Allan is a Professor in the School of Pharmacy at the University of Washington in Seattle. In 1983, he obtained a Ph.D. in Pharmaceutical Sciences from the University of Newcastle-upon-Tyne, England with Professor Sir Michael D. Rawlins. He then moved to Seattle to post-doc with Drs. Mont Juchau and Bill Trager in the areas of extrahepatic drug metabolism and metabolic drug-drug interactions, respectively. Allan joined the faculty of the UW School of Pharmacy in 1987 and was Departmental Chair from 2000-14. His primary research areas are the elucidation of the chemical, enzymatic and genetic bases for adverse drug reactions (ADRs). In 2005, he received the North American Scientific Achievement Award from ISSX for his work on metabolic and genetic mechanisms of ADRs caused by the anticoagulant, warfarin. Allan is past Chair of the IUPHAR Section of Drug Metabolism and Transport (2010-14) and of the Scientific Affairs Committee of ISSX (2013-15). Currently, he is a Member of the Expert Panel for Cosmetic Ingredient Safety in the US.
Nicola Colclough – Principal Scientist, Oncology DMPK at AstraZeneca
Nicola is a principal scientist in oncology DMPK at AstraZeneca, Cambridge, UK and has over 30 years of industrial experience in the drug discovery field. A physical organic chemist by training Nicola gaining her PhD at the University of York, UK working in the group of Professor John Lindsay-Smith studying porphyrins as models for peroxidases and cytochrome P450s. She joined the Structural and Physical Sciences Section at Zeneca at Alderley Park, Cheshire UK where she became Physical Chemistry group leader with responsibility for providing physicochemical property support for all discovery projects at the site including Oncology, Cardiovascular, Respiratory and Inflammation areas. Nicola is currently a DMPK Project Leader within Oncology R & D at AstraZeneca, Cambridge, UK where she works on discovery projects ensuring molecules are designed with good druglike properties. Nicola’s interests include the study of ADME properties and understanding their relationship to molecular structure, covalently binding drugs and the design of molecules targeting the brain.
